Deletion of soluble epoxide hydrolase enhances coronary reactive hyperemia in isolated mouse heart: Role of oxylipins and PPARγ

Ahmad Hanif, Matthew L. Edin, Darryl C. Zeldin, Christophe Morisseau, Mohammed A. Nayeem

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The relationship between soluble epoxide hydrolase (sEH) and coronary reactive hyperemia (CRH) response to a brief ischemic insult is not known. Epoxyeicosatrienoic acids (EETs) exert cardioprotective effects in ischemia/reperfusion injury. sEH converts EETs into dihydroxyeicosatrienoic-acids (DHETs). Therefore, we hypothesized that knocking out sEH enhances CRH through modulation of oxylipin profiles, including an increase in EET/DHET ratio. Compared with sEH+/+, sEH−/−mice showed enhanced CRH, including greater repayment volume (RV; 28% higher,P< 0.001) and repayment/debt ratio (32% higher,P< 0.001). Oxylipins from the heart perfusates were analyzed by LC-MS/MS. The 14,15-EET/14,15-DHET ratio was 3.7-fold higher at baseline (P< 0.001) and 5.6-fold higher post-ischemia (P< 0.001) in sEH−/−compared with sEH+/+mice. Likewise, the baseline 9,10and 12,13-EpOME/DiHOME ratios were 3.2-fold (P< 0.01) and 3.7-fold (P< 0.001) higher, respectively in sEH−/−compared with sEH+/+mice. 13-HODE was also significantly increased at baseline by 71% (P< 0.01) in sEH−/−vs. sEH+/+mice. Levels of 5-, 11-, 12-, and 15-hydroxyeicosatetraenoic acids were not significantly different between the two strains (P> 0.05), but were decreased postischemia in both groups (P = 0.02, P = 0.04, P = 0.05, P= 0.03, respectively). Modulation of CRH by peroxisome proliferator-activated receptor gamma (PPARγ) was demonstrated using a PPARγ-antagonist (T0070907), which reduced repayment volume by 25% in sEH+/+(P< 0.001) and 33% in sEH−/−mice (P< 0.01), and a PPARγ-agonist (rosiglitazone), which increased repayment volume by 37% in both sEH+/+(P = 0.04) and sEH−/−mice (P = 0.04). l-NAME attenuated CRH in both sEH−/−and sEH+/+. These data demonstrate that genetic deletion of sEH resulted in an altered oxylipin profile, which may have led to an enhanced CRH response.

Original languageEnglish (US)
Pages (from-to)R676-R688
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Volume311
Issue number4
DOIs
StatePublished - 2016

Fingerprint

Oxylipins
Epoxide Hydrolases
PPAR gamma
Hyperemia
rosiglitazone
Acids
Reperfusion Injury

Keywords

  • Coronary reactive hyperemia
  • Dihydroxyei-cosatrienoic acids
  • Epoxyeicosatrienoic acids
  • Isolated perfused heart
  • Oxylipins
  • Soluble epoxide hydrolase

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Deletion of soluble epoxide hydrolase enhances coronary reactive hyperemia in isolated mouse heart : Role of oxylipins and PPARγ. / Hanif, Ahmad; Edin, Matthew L.; Zeldin, Darryl C.; Morisseau, Christophe; Nayeem, Mohammed A.

In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology, Vol. 311, No. 4, 2016, p. R676-R688.

Research output: Contribution to journalArticle

Hanif, Ahmad ; Edin, Matthew L. ; Zeldin, Darryl C. ; Morisseau, Christophe ; Nayeem, Mohammed A. / Deletion of soluble epoxide hydrolase enhances coronary reactive hyperemia in isolated mouse heart : Role of oxylipins and PPARγ. In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology. 2016 ; Vol. 311, No. 4. pp. R676-R688.
@article{0bad7f8407604b5cba24d0df9f54713d,
title = "Deletion of soluble epoxide hydrolase enhances coronary reactive hyperemia in isolated mouse heart: Role of oxylipins and PPARγ",
abstract = "The relationship between soluble epoxide hydrolase (sEH) and coronary reactive hyperemia (CRH) response to a brief ischemic insult is not known. Epoxyeicosatrienoic acids (EETs) exert cardioprotective effects in ischemia/reperfusion injury. sEH converts EETs into dihydroxyeicosatrienoic-acids (DHETs). Therefore, we hypothesized that knocking out sEH enhances CRH through modulation of oxylipin profiles, including an increase in EET/DHET ratio. Compared with sEH+/+, sEH−/−mice showed enhanced CRH, including greater repayment volume (RV; 28{\%} higher,P< 0.001) and repayment/debt ratio (32{\%} higher,P< 0.001). Oxylipins from the heart perfusates were analyzed by LC-MS/MS. The 14,15-EET/14,15-DHET ratio was 3.7-fold higher at baseline (P< 0.001) and 5.6-fold higher post-ischemia (P< 0.001) in sEH−/−compared with sEH+/+mice. Likewise, the baseline 9,10and 12,13-EpOME/DiHOME ratios were 3.2-fold (P< 0.01) and 3.7-fold (P< 0.001) higher, respectively in sEH−/−compared with sEH+/+mice. 13-HODE was also significantly increased at baseline by 71{\%} (P< 0.01) in sEH−/−vs. sEH+/+mice. Levels of 5-, 11-, 12-, and 15-hydroxyeicosatetraenoic acids were not significantly different between the two strains (P> 0.05), but were decreased postischemia in both groups (P = 0.02, P = 0.04, P = 0.05, P= 0.03, respectively). Modulation of CRH by peroxisome proliferator-activated receptor gamma (PPARγ) was demonstrated using a PPARγ-antagonist (T0070907), which reduced repayment volume by 25{\%} in sEH+/+(P< 0.001) and 33{\%} in sEH−/−mice (P< 0.01), and a PPARγ-agonist (rosiglitazone), which increased repayment volume by 37{\%} in both sEH+/+(P = 0.04) and sEH−/−mice (P = 0.04). l-NAME attenuated CRH in both sEH−/−and sEH+/+. These data demonstrate that genetic deletion of sEH resulted in an altered oxylipin profile, which may have led to an enhanced CRH response.",
keywords = "Coronary reactive hyperemia, Dihydroxyei-cosatrienoic acids, Epoxyeicosatrienoic acids, Isolated perfused heart, Oxylipins, Soluble epoxide hydrolase",
author = "Ahmad Hanif and Edin, {Matthew L.} and Zeldin, {Darryl C.} and Christophe Morisseau and Nayeem, {Mohammed A.}",
year = "2016",
doi = "10.1152/ajpregu.00237.2016",
language = "English (US)",
volume = "311",
pages = "R676--R688",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - Deletion of soluble epoxide hydrolase enhances coronary reactive hyperemia in isolated mouse heart

T2 - Role of oxylipins and PPARγ

AU - Hanif, Ahmad

AU - Edin, Matthew L.

AU - Zeldin, Darryl C.

AU - Morisseau, Christophe

AU - Nayeem, Mohammed A.

PY - 2016

Y1 - 2016

N2 - The relationship between soluble epoxide hydrolase (sEH) and coronary reactive hyperemia (CRH) response to a brief ischemic insult is not known. Epoxyeicosatrienoic acids (EETs) exert cardioprotective effects in ischemia/reperfusion injury. sEH converts EETs into dihydroxyeicosatrienoic-acids (DHETs). Therefore, we hypothesized that knocking out sEH enhances CRH through modulation of oxylipin profiles, including an increase in EET/DHET ratio. Compared with sEH+/+, sEH−/−mice showed enhanced CRH, including greater repayment volume (RV; 28% higher,P< 0.001) and repayment/debt ratio (32% higher,P< 0.001). Oxylipins from the heart perfusates were analyzed by LC-MS/MS. The 14,15-EET/14,15-DHET ratio was 3.7-fold higher at baseline (P< 0.001) and 5.6-fold higher post-ischemia (P< 0.001) in sEH−/−compared with sEH+/+mice. Likewise, the baseline 9,10and 12,13-EpOME/DiHOME ratios were 3.2-fold (P< 0.01) and 3.7-fold (P< 0.001) higher, respectively in sEH−/−compared with sEH+/+mice. 13-HODE was also significantly increased at baseline by 71% (P< 0.01) in sEH−/−vs. sEH+/+mice. Levels of 5-, 11-, 12-, and 15-hydroxyeicosatetraenoic acids were not significantly different between the two strains (P> 0.05), but were decreased postischemia in both groups (P = 0.02, P = 0.04, P = 0.05, P= 0.03, respectively). Modulation of CRH by peroxisome proliferator-activated receptor gamma (PPARγ) was demonstrated using a PPARγ-antagonist (T0070907), which reduced repayment volume by 25% in sEH+/+(P< 0.001) and 33% in sEH−/−mice (P< 0.01), and a PPARγ-agonist (rosiglitazone), which increased repayment volume by 37% in both sEH+/+(P = 0.04) and sEH−/−mice (P = 0.04). l-NAME attenuated CRH in both sEH−/−and sEH+/+. These data demonstrate that genetic deletion of sEH resulted in an altered oxylipin profile, which may have led to an enhanced CRH response.

AB - The relationship between soluble epoxide hydrolase (sEH) and coronary reactive hyperemia (CRH) response to a brief ischemic insult is not known. Epoxyeicosatrienoic acids (EETs) exert cardioprotective effects in ischemia/reperfusion injury. sEH converts EETs into dihydroxyeicosatrienoic-acids (DHETs). Therefore, we hypothesized that knocking out sEH enhances CRH through modulation of oxylipin profiles, including an increase in EET/DHET ratio. Compared with sEH+/+, sEH−/−mice showed enhanced CRH, including greater repayment volume (RV; 28% higher,P< 0.001) and repayment/debt ratio (32% higher,P< 0.001). Oxylipins from the heart perfusates were analyzed by LC-MS/MS. The 14,15-EET/14,15-DHET ratio was 3.7-fold higher at baseline (P< 0.001) and 5.6-fold higher post-ischemia (P< 0.001) in sEH−/−compared with sEH+/+mice. Likewise, the baseline 9,10and 12,13-EpOME/DiHOME ratios were 3.2-fold (P< 0.01) and 3.7-fold (P< 0.001) higher, respectively in sEH−/−compared with sEH+/+mice. 13-HODE was also significantly increased at baseline by 71% (P< 0.01) in sEH−/−vs. sEH+/+mice. Levels of 5-, 11-, 12-, and 15-hydroxyeicosatetraenoic acids were not significantly different between the two strains (P> 0.05), but were decreased postischemia in both groups (P = 0.02, P = 0.04, P = 0.05, P= 0.03, respectively). Modulation of CRH by peroxisome proliferator-activated receptor gamma (PPARγ) was demonstrated using a PPARγ-antagonist (T0070907), which reduced repayment volume by 25% in sEH+/+(P< 0.001) and 33% in sEH−/−mice (P< 0.01), and a PPARγ-agonist (rosiglitazone), which increased repayment volume by 37% in both sEH+/+(P = 0.04) and sEH−/−mice (P = 0.04). l-NAME attenuated CRH in both sEH−/−and sEH+/+. These data demonstrate that genetic deletion of sEH resulted in an altered oxylipin profile, which may have led to an enhanced CRH response.

KW - Coronary reactive hyperemia

KW - Dihydroxyei-cosatrienoic acids

KW - Epoxyeicosatrienoic acids

KW - Isolated perfused heart

KW - Oxylipins

KW - Soluble epoxide hydrolase

UR - http://www.scopus.com/inward/record.url?scp=84990927946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990927946&partnerID=8YFLogxK

U2 - 10.1152/ajpregu.00237.2016

DO - 10.1152/ajpregu.00237.2016

M3 - Article

C2 - 27488890

AN - SCOPUS:84990927946

VL - 311

SP - R676-R688

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 4

ER -